The Morrison Foerster team representing Seagen Inc. in a recent U.S. Patent Trial and Appeal Board (PTAB) hearing was featured in Law360’s coverage of the decision.
The team persuaded the PTAB to deny a challenge from Daiichi Sankyo Inc. and AstraZeneca Pharmaceuticals to its cancer antibody patent, with the board saying the post-grant review is no longer warranted under the controversial Fintiv precedent. The ruling marked the second time the board has granted a rehearing request in the case and reversed an earlier institution decision. The decision also helps cement Seagen’s $41.8 million jury win in parallel Texas litigation in April.
Michael Jacobs, Matthew Chivvis, Bryan Wilson, Matthew Kreeger, Parisa Jorjani, Sumaiya Sharmeen, Karl Johnston, Chris Han, and Evelyn Chang represented Seagen on the matter.
Read the full article.